Lyra Therapeutics(LYRA) - 2024 Q1 - Quarterly Results

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update WATERTOWN, Mass., April 30, 2024 -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the first quarter ended March 31, 2024 and provided a corporate update. "With results imminent for our ENLIGHTEN 1 pivotal Ph ...